Last reviewed · How we verify

NCT06350565

A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)

Not yet recruiting NA Last updated 16 April 2024
What this trial tests

NA trial testing Dexamethasone in Respiratory Distress Syndrome of Newborn in 48 participants. Not yet recruiting.

Timeline
30 April 2024
Primary endpoint
30 April 2025
31 December 2025

Quick facts

Lead sponsorPeking University Third Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment48
Start date30 April 2024
Primary completion30 April 2025
Estimated completion31 December 2025

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 40, female only, with Respiratory Distress Syndrome of Newborn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study plans to conduct a DEX dose halving study and a normal dose study in 34+0-35+6 GW women with preterm preterm labour. In addition, this study plans to conduct a DEX dose halving study and a normal dose study in 34-38+6 GW preterm pregnant women with GDM or diabetic co-pregnancy to explore the feasibility of dose halving in pregnant women with diabetes mellitus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexamethasone

Trials testing the same drug.

Other recruiting trials for Respiratory Distress Syndrome of Newborn

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06350565.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing